Alex F. Herrera
Led the SWOG S1826 trial that made nivolumab part of first-line Hodgkin lymphoma treatment.
Hematologist-oncologist and study chair of SWOG S1826 (nivolumab-AVD versus brentuximab-AVD), which led to the 2026 approval of nivolumab in untreated advanced Hodgkin lymphoma. Executive officer for SWOG's haematologic committees.
| Title | Journal | Year |
|---|---|---|
| Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma | New England Journal of Medicine | 2024 |
| Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma | Blood | 2018 |
Pages like this
not linked directly; found by shared links- PairingPD-1 blockade + AVD chemotherapy
Shares SWOG S1826, SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Hodgkin lymphoma, Nivolumab.
- TrialAHOD2131 (COG / NCTN)
Shares SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Brentuximab vedotin, Hodgkin lymphoma, Nivolumab.
- PersonSteven T. Rosen
- PersonVirginia Sun
Shares City of Hope, SWOG Cancer Research Network.
- Key paperECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma
Shares SWOG S1826, SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Brentuximab vedotin, Hodgkin lymphoma.
- TrialKEYNOTE-204
Shares Brentuximab vedotin, Hodgkin lymphoma.
- TargetCD30
Shares SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Brentuximab vedotin, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- TrialECHELON-1
Shares SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Brentuximab vedotin, Hodgkin lymphoma.